Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, United States Department of Justice, Washington, DC 20537, Attention: DEA Federal Register Representative (CCD) and must be filed no later than December 29, 2003.

Dated: October 7, 2003.

### Laura M. Nagel,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 03–27238 Filed 10–28–03; 8:45 am]

BILLING CODE 4410-09-M

## **DEPARTMENT OF JUSTICE**

# **Drug Enforcement Administration**

# Manufacturer of Controlled Substances; Notice of Registration

By notice dated June 6, 2003, and published in the **Federal Register** on June 19, 2003, (68 FR 36844), Eli-Elsohly Laboratories, Inc., Mahmoud A. Elsohly, Ph.D., 5 Industrial Park Drive, Oxford, Mississippi 38655, made application by renewal to the Drug Enforcement Administration to be registered as a bulk manufacturer of the basic classes of Schedules I and II controlled substances listed below:

Drug	Schedule
Tetrahydrocannabinols (7370) Dihydromorphine (9145) Codeine (9050) Amphetamine (1100) Methamphetamine (1105) Cocaine (9041) Codeine (9050) Dihydrocodeine (9120) Oxycodone (9143) Hydromorphone (9150) Benzoylecognine (9180) Hydrocodone (9193) Morphine (9300)	

The firm plans to manufacture nondeuterated controlled substances for use as analytical standards and deuterated controlled substances for use as internal standards.

No comments or objections have been received. DEA has considered the factors in title 21, United States Code, section 823(a) and determined that the registration of Eli-Elsohly Laboratories, Inc. to manufacture the listed controlled substances is consistent with the public interest at this time. DEA has investigated Eli-Elsohly Laboratories, Inc. to ensure that the company's registration is consistent with the public interest. This investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with state

and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 823 and 28 CFR 0.100 and 0.104, the Deputy Assistant Administrator, Office of Diversion Control, hereby orders that the application submitted by the above firm for registration as a bulk manufacturer of the basic classes of controlled substances listed is granted.

Dated: October 15, 2003.

#### Laura M. Nagel,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 03–27243 Filed 10–28–03; 8:45 am] BILLING CODE 4410–09–M

## **DEPARTMENT OF JUSTICE**

## **Drug Enforcement Administration**

## Manufacturer of Controlled Substances; Notice of Application

Pursuant to Section 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on August 1, 2003, Gateway Speciality Chemical, Co., 4170 Industrial Drive, St. Peters, Missouri 63376, made application by renewal to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of phenylacetone (8501), a basic class of controlled substance listed in Schedule II.

The firm plans to manufacture the controlled substance for its customers.

Any other such applicant and any person who is presently registered with DEA to manufacture such substance may file comments or objections to the issuance of the proposed registration.

Any such comments or objections may be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, United States Department of Justice, Washington, DC 20537, Attention: Federal Register Representative, Office of Chief Counsel (CCD) and must be filed no later than December 29, 2003.

Dated: October 7, 2003.

# Laura M. Nagel,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 03-27239 Filed 10-28-03; 8:45 am]

BILLING CODE 4410-09-M

## **DEPARTMENT OF JUSTICE**

## **Drug Enforcement Administration**

# Manufacturer of Controlled Substances Notice of Application

Pursuant to section 1301.33(a) of title 21 of the Code of Federal Regulations (CFR), this is notice that on August 6, 2003, Guilford Pharmaceuticals, Inc., 6611 Tributary Street, Baltimore, Maryland 21224, made application by renewal to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of cocaine (9041) a basic class of controlled substance listed in Schedule II.

The firm plans to manufacture a Schedule II cocaine derivative as a final intermediate for the production of dopascan injection.

Any other such applicant and any person who is presently registered with DEA to manufacture such substances may file comments or objections to the issuance of the proposed registration.

Any such comments or objections may be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, United States Department of Justice, Washington, DC 20537, Attention: Federal Register Representative, Office of Chief Counsel (CCD) and must be filed no later than [December 29, 2003].

Dated: October 7, 2003.

## Laura M. Nagel,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 03–27240 Filed 10–28–03; 8:45 am] BILLING CODE 4410–09–M

# **DEPARTMENT OF JUSTICE**

# **Drug Enforcement Administration**

# Manufacturer of Controlled Substances; Notice of Application

Pursuant to section 1301.33(a) of title 21 of the Code of Federal Regulations (CFR), this is notice that on August 5, 2003, ISP Freetown Fine Chemicals, Inc., 238 South Main Street, Freetown, Massachusetts, made application by renewal to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of the basic classes of controlled substances listed below:

Drug	Schedule
2,5-Dimethoxyamphetamine (7396).	1
Amphetamine (1100) Phenylacetone (8501)	II II